Should I ignore industry-funded research?

No, and it is not practical to. Almost all pivotal drug trials are sponsor-funded, because almost nobody else funds them. The realistic approach is to read them with their sponsorship known and to weight corroboration from differently biased sources heavily.

What is a medical communications agency doing on an author list?

Providing statistical analysis, writing and editorial support under contract, which is common and legitimate when disclosed. The relevant question is whether their role is stated - here it is, including which individuals did the statistical work and who paid for it - rather than whether they were involved.

Does an author holding shares matter more than receiving honoraria?

They are different kinds of interest. Equity ties personal wealth to a company's performance in a continuing way; an honorarium is a discrete payment. Both are disclosed for a reason and neither is automatically decisive.

Where do I find these statements?

In the paper itself, usually under Declarations, Funding, or Conflict of Interest near the end, and in the full text rather than the abstract. Abstract-only reading is how most conflicts go unnoticed, because the abstract never carries them.

GLP-1 & Incretin Science

Disclosure Is Not Disqualification

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

A conflict of interest statement tells you who paid, who was employed, and who held stock. It does not tell you whether a paper is right. The useful move is to identify the judgement calls only the authors could make and weigh those against the declared interest.

Key facts

Worked example: Ciudin et al., Adv Ther 2026 (PMID 41820778)
Funding statement: Sponsored by Eli Lilly, which also funded rapid service and open access fees
Employee authors: 5 of 9 declared as employees and shareholders of Eli Lilly
Contracted authors: 3 employed by Costello Medical, paid by Lilly for analytical services
Independent author: 1, declaring honoraria from four companies including Lilly
Medical writing: Costello Medical, funded by Eli Lilly
Drug favoured by result: Tirzepatide, marketed by Eli Lilly
Data availability: From the corresponding author on reasonable request

What the statement actually contains

Take the 2026 Bayesian network meta-analysis of tirzepatide, semaglutide and liraglutide as a worked example, because its declarations are unusually complete. The funding statement says the study was sponsored by Eli Lilly and that Lilly also paid the journal's rapid service and open access fees. The conflict of interest section names five authors as employees and shareholders of Eli Lilly and Company, three as employees of Costello Medical which received payment from Lilly for analytical services for this study, and one - the lead author, a clinician - as receiving honoraria from AstraZeneca, Boehringer Ingelheim, Lilly and Novo Nordisk. A separate acknowledgement names the medical writing and statistical support, also at Costello Medical, also funded by Lilly. The result favours tirzepatide, which is Lilly's product.

Why complete disclosure is a good sign, not a bad one

It is tempting to treat a long conflicts section as a warning. It is closer to the opposite. Everything above is knowable only because the paper states it, in a standard place, in plain language. The papers worth worrying about are the ones where the funding is vague, the writing assistance is unacknowledged, or the analytical contractor is invisible. A disclosure this granular hands the reader exactly what they need to scrutinise the work, and the reader's job is to use it rather than to treat it as a verdict.

What sponsorship does and does not predict

There is a substantial literature showing that industry-sponsored studies more often report conclusions favourable to the sponsor than independently funded studies of the same questions. That is an association across bodies of literature, and it is a legitimate reason to apply extra scrutiny to any single sponsored paper. It is not a finding about any individual study, and treating it as one is a category error - it would require discarding most of the evidence base for most licensed medicines, since pivotal trials are almost universally sponsor-funded.

Locate the discretionary decisions

The productive question is not 'was this sponsored' but 'where could a sponsor's preference have entered'. In a randomised trial, most of the structure is fixed in a protocol and registered in advance, which constrains discretion considerably. In a meta-analysis the discretion is much larger and sits in the inclusion criteria: this analysis identified 42 randomised trials and included six. Which six is the single most consequential decision in the paper, it was made by the analysts, and it is where scrutiny belongs. The stated reason - a heterogeneity assessment requiring comparable design, population, background therapy and estimands - is a legitimate one, and the six trials are named so the reasoning can be checked against the supplementary material.

Then look for the external check

The strongest response to a conflict of interest is not suspicion but corroboration. This analysis estimated tirzepatide 15 mg at 6.26 percentage points better than semaglutide 2.4 mg on weight. SURMOUNT-5, a head-to-head trial the authors state was published after their analysis was conducted and which they excluded, found 6.5 percentage points. SURMOUNT-5 was itself Lilly-funded, so that is not fully independent corroboration - but it is a prospectively randomised, registered comparison rather than an analyst's reconstruction, and the agreement is close. Independent real-world cohorts point the same direction with smaller effects. Convergence from designs with different biases is worth more than any declaration.

A short procedure

Read the funding statement and the conflicts section before the results, so the results do not colour how you read them. Identify who employed the analysts as distinct from who employed the clinicians. Find the decisions that were discretionary rather than protocol-bound. Check whether those decisions are documented well enough to audit. Then look for whether anything with a different set of biases agrees. If the answer to the last two is yes, the declared interest is information you hold rather than a reason to discard the work.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Should I ignore industry-funded research?: No, and it is not practical to. Almost all pivotal drug trials are sponsor-funded, because almost nobody else funds them. The realistic approach is to read them with their sponsorship known and to weight corroboration from differently biased sources heavily.
What is a medical communications agency doing on an author list?: Providing statistical analysis, writing and editorial support under contract, which is common and legitimate when disclosed. The relevant question is whether their role is stated - here it is, including which individuals did the statistical work and who paid for it - rather than whether they were involved.
Does an author holding shares matter more than receiving honoraria?: They are different kinds of interest. Equity ties personal wealth to a company's performance in a continuing way; an honorarium is a discrete payment. Both are disclosed for a reason and neither is automatically decisive.
Where do I find these statements?: In the paper itself, usually under Declarations, Funding, or Conflict of Interest near the end, and in the full text rather than the abstract. Abstract-only reading is how most conflicts go unnoticed, because the abstract never carries them.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum